| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbffa3b81b3b862dc7220b5648f5f745 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate |
2019-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e21bbb15fdc9a05af0343336ba7024c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e43392ef1de5635d2ebabc3f20bdf9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d676a285f5aa778aebb1ffd50f99204 |
| publicationDate |
2021-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20210039846-A |
| titleOfInvention |
Use of src inhibitor for overcoming drug resistance of cancer |
| abstract |
The present invention relates to the use of SRC as a novel combination drug target capable of overcoming drug resistance of a target anticancer agent. The SRC inhibitor according to the present invention inhibits the key feedback that causes drug resistance of the target anticancer agent, and increases the anticancer effect when administered in combination with a target anticancer agent that inhibits the MAPK and PI3K signaling pathways. Accordingly, the present invention can overcome resistance to target anticancer agents and increase the treatment accuracy rate for anticancer agents of cancer patients, thereby presenting new possibilities for treatment strategies using target anticancer agents, and contributing to the realization of precision medicine. |
| priorityDate |
2019-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |